2016-004318-82
A study comparing Tobramycin Inhalation Powder (TIP) administered once daily continuously versus TIP administered BID in 28 day on / 28 day off cycles for the treatment of pulmonary Pseudomonas aeruginosa in patients with cystic fibrosis
Novartis Pharmaceuticals Corporation·EU Clinical Trials Register
Study focus
- Disease/Condition
- Cystic Fibrosis
Sponsor & location
- Primary sponsor
- Novartis Pharmaceuticals Corporation
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
ICD-10 classifications
Pseudomonas (aeruginosa) as the cause of diseases classified to other chaptersPneumonia due to PseudomonasCongenital pneumonia due to PseudomonasBacterial infection, unspecifiedBacterial infection of unspecified site
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2016-004318-82
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2016-004318-82 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharmaceuticals Corporation and is currently status unknown. The study focuses on Cystic Fibrosis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.